Literature DB >> 27694503

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Thomas Prebet1, Pierre Fenaux2, Norbert Vey3.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; cytogenics and molecular genetics; hypomethylating agents; melodysplastic syndromes; stem cell transplantation

Mesh：

Substances：

Year:  2016        PMID： 27694503      PMCID： PMC5046667          DOI： 10.3324/haematol.2016.150714

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.

Authors:  Thomas Prébet; Sylvain Thepot; Steven D Gore; François Dreyfus; Pierre Fenaux; Norbert Vey
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

2.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

3.  The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.

Authors:  Aziz Nazha; Rami S Komrokji; Guillermo Garcia-Manero; John Barnard; Gail J Roboz; David P Steensma; Amy E DeZern; Katrina Zell; Cassie Zimmerman; Najla Al Ali; Elias Jabbour; Molly D Greenberg; Hagop M Kantarjian; Jaroslaw P Maciejewski; Alan F List; Mikkael A Sekeres
Journal:  Haematologica       Date:  2016-03-18       Impact factor: 9.941

4.  Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Sylvain Thépot; Benjamin Esterni; Bruno Quesnel; Odile Beyne Rauzy; François Dreyfus; Claude Gardin; Pierre Fenaux; Norbert Vey
Journal:  Br J Haematol       Date:  2012-03-06       Impact factor: 6.998

5.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860
  7 in total
  3 in total

1.  NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.

Authors:  Elizabeth A Griffiths; Pragya Srivastava; Junko Matsuzaki; Zachary Brumberger; Eunice S Wang; Justin Kocent; Austin Miller; Gregory W Roloff; Hong Yuen Wong; Benjamin E Paluch; Linda G Lutgen-Dunckley; Brandon L Martens; Kunle Odunsi; Adam R Karpf; Christopher S Hourigan; Michael J Nemeth
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 13.801

Review 2.  The MDS genomics-prognosis symbiosis.

Authors:  Aziz Nazha
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Authors:  Aziz Nazha; Mikkael A Sekeres; Rami Komrokji; David P Steensma; Hagop Kantarjian; Gail Roboz; Pierre Fenaux; Thomas Prebet; Nozar Azarnia; Patrick S Zbyszewski; Steven M Fruchtman; Valeria Santini; Lewis R Silverman; Uwe Platzbecker; Guillermo Garcia-Manero
Journal:  Blood Cancer J       Date:  2017-12-14       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.